SELECTIVE ANTI-MARCKS TECHNOLOGIES

biomarck is developing technology that utilizes targeted anti-Marcks technology for the treatment of Cancer and Acute Respiratory Distress Syndrome (ARDS)

Learn How

The Discovery

Utilizing targeted anti-Marcks peptides in order to develop and license products targeted at difficult to treat diseases with unmet needs.

Learn More

 

Publications

Cancer_pub_new

Cancer

1.Anti-MARCKS Peptides Inhibit Lung Cancer Metastasis in Mice

2.Inhibition of Lung Cancer Metastasis in mice by inhaled aerosolized anti-MARCKS peptides

3.MicroRNA-21 (miR-21) Affects Migration of Human Lung Cancer Cells in vitro via Regulation of MARCKS Expression

4.MARCKS Protein Inhibitors Attenuate Cancer Cell Migration/Metastasis

5.Regulated mucin secretion from airway epithelial cells

6.A Novel Predictor of Cancer Malignancy: Up-regulation of Myristoylated Alanine-Rich C Kinase Substrate Phosphorylation in Lung Cancer

ARDS_pub_1

ARDS

1.Anti-MARCKS Peptides Reverse LPS-induced Acute Respiratory Distress Syndrome (ARDS) in Mice

2.A peptide that inhibits function of Myristoylated Alanine-Rich
C Kinase Substrate (MARCKS) reduces lung cancer metastasis

COPD_pub_new

COPD

1.Enhanced Expression of Myristoylated Alanine – Rich C Kinase Substrate (MARCKS) in Airway Epithelium of an Animal Model of Allergic Airway Inflammation and Human Patients with COPD

2.An Inhaled Inhibitor of Myristoylated Alanine-Rich C Kinase Substrate
Reverses LPS-Induced Acute Lung Injury in Mice

See All

For Children

biomarck pharmaceuticals intends to support children with difficult to treat cancers such as Rhabdomyosarcoma and Neuroblastoma. This may be done by a compassionate use program under the Investigator IND of the treating hospital. This effort will be done in support of the concepts of non-profit organizations such as the Miami based Live Like Bella Foundation (Learn More) which supports children with cancer, their families and research into childhood cancer.

Visit Live Like Bella

INVESTORS

Letter to Biomarck Investors

Biomarck Overview

Learn More